Medpage Today on MSN3mon
Novel Monoclonal Antibody Protects Infants Against RSVThe investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV) disease and prevented ...
New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...
Because RSV, influenza, and COVID-19 share symptoms, accurate testing is needed to distinguish one from the other. This CE-IVD marked multiplex PCR test is specifically designed to detect and ...
Glamour on MSN3mon
RSV Symptoms: Here’s How the Virus Shows Up Differently in Babies, Adults, and SeniorsHealthy adults and older children don’t usually need RSV testing, though some at-home kits test for Covid-19 ... with the injectable RSV monoclonal antibody, nirsevimab, between March and ...
This week, The FDA accepted Merck & Co.’s biologics license application for the monoclonal antibody clesrovimab, which works differently from a vaccine but also provides protection against RSV.
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...
Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback